Revolution Medicines' Pancreatic Cancer Drug Daraxonrasib Shows Promising Results in Late-Stage Trial
Revolution Medicines has announced that its pancreatic cancer drug, daraxonrasib, has succeeded in a Phase 3 trial, demonstrating significant improvements in patient survival rates. The trial results revealed that patients taking daraxonrasib lived for an average of 13.2 months compared to 6.7 months for those on chemotherapy, effectively doubling the survival period. The drug targets RAS mutations, which are present in approximately 90% of pancreatic cancer cases. The company plans to seek FDA approval using a Commissioner's National Priority Voucher, which could expedite the review process. The drug's safety profile was deemed manageable, with rash being a known side effect. 
